INFILTRATING LEUKOCYTES regulate tumor progression through secretion of soluble factors or through direct targeting of tumor cells or stroma (1) , but the role of tumor-derived growth factors in modulating the response to inflammatory stimuli is still largely unknown. Immune cell recruitment is controlled through endothelial upregulation of various adhesion molecules and chemokines that mediate leukocyte capture, rolling on the endothelium, firm adhesion, and finally, leukocyte transmigration to the inflammatory site (2) . This process is initiated by inflammatory cytokines, such as TNF-a, mainly through activation of the NF-kB pathway. In response to inflammatory cytokines, IkB is ubiquitinated and degraded, leading to nuclear translocation of the NF-kB complex and expression of molecules that mediate endothelial-leukocyte interactions, including E-selectin, intercellular adhesion molecule-1 (ICAM-1), and VCAM-1 (3) . Endothelial cells isolated from tumors are less responsive to proinflammatory stimuli and express lower levels of several molecules involved in leukocyte recruitment (4, 5) .
VEGF is the most prominent, proangiogenic growth factor in tumors, its expression correlating with higher vascular density and poor prognosis in several types of cancer. Antiangiogenic therapies targeting the VEGF signaling pathway are in clinical use as cancer therapeutic Abbreviations: BSA, bovine serum albumin; CSF2, colonystimulating factor 2; DEPC, diethylpyrocarbonate; FACS, fluorescence-activated cell sorting; FCS, fetal calf serum; FGF, fibroblast growth factor; fwd, forward; h, human; HDMEC, human dermal microvascular endothelial cell; HPRT, hypoxanthine-guanine phosphoribosyltransferase; HRP, horseradish peroxidase; IC 50 , 50% inhibition/inhibitory concentration; ICAM-1, intercellular adhesion molecule 1; IFN, interferon; IRF-1, IFN regulatory factor 1; ISRE, IFN-sensitive response element; m, mouse; NF-kB, nuclear factor k-light-chain-enhancer of activated B cells; p, phosphorylated; qRT-PCR, quantitative RT-PCR; rev, reverse; siRNA, small interfering RNA; Stat1, signal transducer and activator of transcription 1; TBS, Tris-buffered saline; TNFRSF9, TNF superfamily receptor 9; TNFSF15, TNF superfamily 15; VE, vascular endothelial agents, but the success has been limited, and the net effect of these therapies on modulating vascular phenotype and thereby, altering the tumor microenvironment has not been thoroughly investigated. Several lines of evidence suggest that expression of VEGF may affect immune cell infiltration. High levels of proangiogenic factors drive endothelial cell proliferation in tumors, giving rise to structurally and functionally abnormal vessels. These irregularly shaped vessels, which are leaky, tortuous, and lack normal vascular hierarchy, may constitute a barrier for leukocyte infiltration (6) (7) (8) . The interference with VEGF signaling, by targeting VEGF or VEGFR2, normalizes the tumor vasculature, decreases tumor vascular density, and increases the effectiveness of adoptive T-cell therapy in B16 melanoma (9) . Treatment with the tyrosine kinase inhibitor sunitinib that targets VEGFR signaling increases the efficacy of specific vaccination or immunotherapy associated with increased T cell infiltration and reduced accumulation of myeloid-derived suppressor cells (10, 11) . VEGF stimulation of endothelial cells may act as a positive or a negative regulator of endothelial activation through modulation of NF-kB signaling and adhesion molecule expression. Whereas acute stimulation with VEGF up-regulates adhesion molecule expression in vitro and increases leukocyte infiltration in vivo, long-term exposure to VEGF inhibits endothelial-leukocyte interactions by down-regulating expression of the adhesion molecules ICAM-1, VCAM-1, and E-selectin and decreasing the responsiveness to proinflammatory cytokines (4, 12) . Treatment with angiogenesis inhibitors, including anginex, endostatin, and angiostatin, stimulates endothelialleukocyte interaction in tumors and increases adhesion molecule expression (13) . Notably, the molecular mechanisms that underlie VEGF-induced suppression of adhesion molecule expression and its reversal through antiangiogenic therapy are not clear, and the net effect of VEGF in modulating expression of proinflammatory genes in endothelial cells has not been investigated. The wide use of antiangiogenic treatment in the clinic and the central role of leukocytes in regulating the tumor microenvironment warrant investigations to determine how antiangiogenic treatment targeting the VEGF pathway affects endothelial gene expression and thereby, modulates leukocyte recruitment.
In this manuscript, we demonstrate that VEGF suppresses leukocyte recruitment through modulating endothelial expression of a wide range of proinflammatory genes, including the T-lymphocyte-attracting chemokines CXCL10 and CXCL11, and immunomodulatory molecules, such as colony-stimulating factor 2 (CSF2), TNF superfamily 15 (TNFSF15), and 4-1BB. Importantly, we show that VEGF inhibits endothelial activation by interfering directly with IkB degradation, leading to reduced activation of NF-kB. Short-term inhibition of VEGF signaling by sunitinib treatment of B16 melanoma tumor-bearing mice is sufficient to increase expression of CXCL10 and CXCL11 in tumor vessels, enhancing T-lymphocyte infiltration, specifically in the inner mass of the tumor. Our results suggest that VEGF-mediated inhibition of NF-kB signaling and subsequent reduction of chemokine expression contribute to endothelial cell anergy in tumors and that endothelial activation and lymphocyte recruitment are restored by short-term pharmacological targeting of VEGF signaling.
MATERIALS AND METHODS

In vitro stimulation of endothelial cells
Human dermal microvascular endothelial cells (HDMEC; 3H Biomedical, Uppsala, Sweden) and HUVEC (3H Biomedical) were cultured on gelatin-coated tissue-culture dishes in complete endothelial cell growth medium (EBM-MV2; PromoCell, Heidelberg, Germany). HDMEC were seeded on 6-well plates and the next day, treated with 1 ng/ml TNF-a (PeproTech, Rocky Hill, NJ, USA), 50 ng/ml VEGF (PeproTech), 1 mM sunitinib (LC Laboratories, Woburn, MA, USA), or 10 mM SB203580 (SelleckChem, Munich, Germany) in endothelial basal medium containing 1% FCS.
Model for endothelial-leukocyte adhesion
To study endothelial-leukocyte adhesion, a microfluidic device, as described previously for studying endothelial migration (14) , was modified to allow leukocyte rolling on endothelial cells (Fig. 1A) . Jurkat cells were loaded to the silicon chamber and pumped into a channel under 4 ml/min flow speed using a syringe pump (NE-1002X; New Era Pump Systems, Farmingdale, NY, USA), enabling Jurkat cells to interact with a monolayer of pretreated endothelial cells (HDMEC). Adhesion of leukocytes to the endothelial monolayer was monitored using an Axiovert timelapse microscope (Zeiss, Oberkochen, Germany). Images of 5 distinct areas of the channel were taken every 30 s, and a total of 30 images were collected. The number of Jurkat cells adhering to the endothelial monolayer was quantified by ImageJ software.
FACS analysis
Endothelial cells were detached using 0.05% trypsin in PBS + 1 mM EDTA and resuspended in fluorescence-activated cell sorting (FACS) buffer (1% FCS + 0.02% NaN 3 in PBS). Cells were incubated with anti-human ICAM-1 (BBA3; R&D Systems, Minneapolis, MN, USA), anti-human VCAM-1 (eBioscience, San Diego, CA, USA), anti-human E-selectin (BBIG-E4; R&D Systems), or mouse control IgG1 (Becton Dickinson, Franklin Lakes, NJ, USA) for 30 min at 4°C, washed once with FACS buffer, and subsequently incubated in Alexa 488-conjugated donkey anti-mouse IgG (Life Technologies, Carlsbad, CA, USA), diluted in FACS buffer for another 30 min at 4°C. Just before LSR II (Becton Dicksinon) FACS analysis, DAPI was added to discriminate dead cells from living cells.
ELISA
Soluble CXCL10 was measured using a commercial ELISA kit (R&D Systems), according to the manufacturer's instructions. Briefly, cell culture supernatant was collected and incubated together with Assay Diluent for 2 h at room temperature in the antibody-precoated plates. Each well was washed 4 times and incubated with the horseradish peroxidase (HRP)-conjugated detection antibody for 2 h at room temperature. After washing, the wells were incubated with substrate for 30 min at room temperature, and immediately after stopping the reaction with stop solution, the optical density was measured at 450 nm by use of a microplate reader (Molecular Devices, Sunnyvale, CA, USA).
Western blot
Cells were lysed in lithium dodecyl sulfate sample buffer with 5% reducing agent (Life Technologies). After homogenization by pipetting and denaturation at 70°C for 10 min, samples were loaded onto NuPage 4-12% Bis-Tris gels (Life Technologies) in 3-(N-morpholino)propanesulfonic acid (MOPS) buffer, separated by electrophoresis at 200 V, and transferred to Hybond-C membrane (GE Healthcare, Chalfont St. Giles, United Kingdom) at 30 V for 2 h. Membranes were blocked in 5% dry milk or 1% milk + 1% BSA in Tris-buffered saline (TBS) for phosphorylated proteins for 60 min and incubated with anti-human b-catenin (610153; Becton Dickinson), anti-actin (sc1615; Santa Cruz Biotechnology, Dallas, TX, USA), anti-b2-microglobulin (ab75853; Abcam, Cambridge, United Kingdom), anti-human IkB (sc-371; Santa Cruz Biotechnology), anti-human p-ser-IKKa/b (#2697; Cell Signaling Technology, Danvers, MA, USA), anti-IRF-1 (sc497; Santa Cruz Biotechnology), anti-human p-Stat1 (#9167; Cell Signaling Technology), anti-Stat1 (sc346; Santa Cruz Biotechnology), anti-p-Stat3 (#9145; Cell Signaling Technology), anti-Stat3 (#4904; Cell Signaling Technology), anti-p-p38 (#9211; Cell Signaling Technology), anti-VEGFR2 (AF357; R&D Systems), or anti-p-Y1175 VEGFR2 (#2478; Cell Signaling Technology) for 2 h at room temperature. Primary antibodies were diluted in 5% milk in TBS, and primary antibodies to phosphorylated antigens were diluted in 1% BSA + 1% milk in TBS. Membranes were washed in TBS + 0.1% Tween-20 and incubated with HRP-conjugated antirabbit, HRP-conjugated anti-mouse (GE Healthcare), or HRPconjugated anti-goat (Dako, Glostrup, Denmark) for 1 h at room temperature. Finally, membranes were developed using ECL Prime substrate (GE Healthcare) for 5 min and exposed to ECL hyperfilm (GE Healthcare).
RNA extraction, cDNA synthesis, and quantitative real-time RT-PCR RNA from endothelial cells was extracted using the RNeasy Mini Plus Kit (Qiagen, Hilden, Germany), and the RNA yield was measured using NanoDrop 2000. RNA was reverse transcribed using SuperScript III (Life Technologies), and quantitative (q) PCR analysis was performed using SYBR Green (Life Technologies) in triplicate for each sample. Human (h) or mouse (m) hypoxanthine-guanine phosphoribosyltransferase (HPRT) was used as internal control. Primer sequences are listed as the following: hHPRT forward (fwd): CTTTGCTGACCTGCTGGA-TT, hHPRT reverse (rev): TCCCCTGTTGACTGGTCATT; hCX CL10 fwd: GGGTCTGAGTGGGACTCAAGGGAT, hCXCL10 rev: GGCCCTCATTCTCACTGGCCC; hCXCL11 fwd: GCCAC-AGCTGCTCAAGGCTTC, hCXCL11 rev: GCCATTTTGACGG-CTTTCATCCCG; hTNFRSF9 fwd: AGAGGGACGTGGTCTGT-GGACC, hTNFRSF9 rev: AGAGTGTCCTGGCTCTCTCGCA; hCSF2 fwd: CCGGCGTCTCCTGAACCTGA, hCSF2 rev: AGG-CGGGTCTGTAGGCAGGTC; hVEGFR2 fwd: GGAATGGTGCC-CAGCAAA, hVEGFR2 rev: TGGTAGCCGCTTGTCTGGTT; hC1QTNF1 fwd: TTGGCCGGCGGGAGATGCTCTAG, hC1QTNF1 rev: AGTACGCCAGCAAGAGTCCCTGT; mHPRT fwd: CAAA-CTTTGCTTTCCCTGGT, mHPRT rev: TCGAGAGGTCCTTTT-CACC; mICAM-1 fwd: CCGCTACCATCACCGTGTA, mICAM-1 rev: CAGAGGTCTCAGCTCCACACT; mVCAM-1 fwd: TGGGA-AGCTGGAACGAAGTA, mVCAM-1 rev: CTCTGGATCCTTG-GGGAAA; mE-selectin fwd: GCGCTTTCTCTCTGCTCTTG, mE-selectin rev: ATGAGCTCACTGGAGGCATT; mCD31 fwd: TACTGCAGGCATCGGCAAA, mCD31 rev: GCATTTCGCA-CACCTGGAT; m-vascular endothelial (VE)-cadherin fwd: AGGACAGCAACTTCACCCTCA, mVE-cadherin rev: AAC-TGCCCATACTTGACCGTG; mCXCL10 fwd: GGGTCTGAG-TGGGACTCAAGGGAT, mCXCL10 rev: GGCCCTCATTCT-CACTGGCCC; mCXCL11 fwd: GCCACAGCTGCTCAAGG-CTTC, mCXCL11 rev: GCCATTTTGACGGCTTTCATCC-CG; mTNFRSF9 fwd: ACCTTTGGTGTCCTGT-GCATGTGA, mTNFRSF9 rev: GTTCTGCACGGCTCCCACCT; mTNFSF15 fwd: GGAAAAGACTGTATGCTTCGGGCCA, mTNFSF15 rev: TCGGCTTGCCTCTGGGAGGT; mCSF2 fwd: TCGAGCAG GGTCTACGGGGC, mCSF2 rev: GTCCGTTTCCGGAGTTG GGGG; mVEGFA fwd: AAGGAGAGCAGAAGTCCCATGA, mVEGFA rev: CTCAATTGGACGGCAGTAGCT; mTNFA fwd: GTCTACTGAACTTCGGGGTGA, mTNFA rev: AGGGTCTG GGCCATAGAACT.
Immunofluorescence staining
Cryosections were fixed with ice-cold acetone for 15 min and blocked with 3% BSA in PBS for 1 h at room temperature. Sections were incubated with primary antibodies against CD31 (553370; Becton Dickinson) and CD3 (MB4841; R&D Systems) for 2 h at room temperature. After extensive washing with PBS, 3 times, sections were incubated with Alexa 555-conjugated goat anti-rat IgG (A21424; Life Technologies) for 1 h at room temperature. Sections were counterstained with Hoechst 33342 to visualize the nuclei and mounted with Fluoromount-G (Southern Biotechnology, Birmingham, AL, USA) before images were taken on a Nikon Eclipse 80i microscope. Tumor area was quantified by ImageJ software, and CD3-positive cells were counted manually.
Laser microdissection
Cryosections (10 mm) of the B16.F10 tumor specimen on polyester membrane slides (Leica Microsystems, Wetzlar, Germany) were fixed in acetone and stained with FITC-conjugated Isolectin B4 (Vector Laboratories, Burlingame, CA, USA), diluted in diethylpyrocarbonate (DEPC)-treated PBS for 2 min. The slides were rinsed 3 times with DEPC-treated water and air dried. Vessels were microdissected using an LMD6500 laser microdissection microscope (Leica Microsystems). From each specimen, an ;1 3 10 6 mm 2 vessel area was dissected and collected in RLT buffer (Qiagen). RNA was extracted using RNeasy Micro kit (Qiagen).
Affymetrix microarray
RNA concentration was measured with ND-1000 spectrophotometer (NanoDrop Technologies, Wilmington, DE, USA), and RNA quality was evaluated using the Agilent 2100 bioanalyzer system (Agilent Technologies, Palo Alto, CA, USA). Total RNA (250 ng) from each sample was used to generate amplified and biotinylated sense-strand cDNA from the entire expressed genome, according to the Ambion WT Expression Kit (P/N 4425209 Rev B 05/2009) and GeneChip WT Terminal Labeling and Hybridization User Manual (P/N 702808 Rev. 1; Affymetrix, Santa Clara, CA, USA). Human Gene 1.0 ST arrays (Affymetrix) were hybridized for 16 h in a 45°C incubator and rotated at 60 rpm. According to the GeneChip Expression Wash, Stain and Scan Manual (PN 702731 Rev 2; Affymetrix), the arrays were then washed and stained using the Fluidics Station 450 and finally scanned using the GeneChip Scanner 3000 7G.
Microarray data analysis
Subsequent analysis of the gene expression data was carried out in the freely available statistical computing language R (http://www. r-project.org) by use of packages available from the Bioconductor project (www.bioconductor.org). The raw data were normalized using the robust multiarray average method, first suggested by Li and Wong in 2001 (15, 16) . The normalization, on the other hand, was carried out in the Affymetrix software Expression Console. To search for differentially expressed genes among the different groups, an empirical Bayes-moderated t-test was then applied, using the "limma" package (17) .
Animal experiments
Male, 7-to 8-wk-old C57BL/6 wild-type mice were obtained from Taconic M&B (Bomholt, Denmark). Mice received 5 3 10 5 B16. F10 cells subcutaneously on day 0. On day 10, tumor-bearing mice were randomized into 3 groups, and sunitinib (at a dose of 50 mg/kg) or vehicle (carboxymethylcellulose sodium 0.5% wt/vol, NaCl 1.8% wt/vol, Tween-80 0.4% wt/vol, benzyl alcohol 0.9% wt/vol, and H 2 O, pH 6.0) was administered via oral gavage for 4 consecutive days, or vehicle was administered for 3 days and sunitinib for 1 day. Mice were killed on day 16, and B16 tumors were dissected and snap frozen on isopentane/dry ice.
All animal work was performed according to the guidelines for animal experimentation and welfare provided by Uppsala University and approved by a regional Ethics Committee.
Statistical analysis
Statistical analysis was performed using ANOVA or unpaired Student's t-test using GraphPad Prism 6.0 (GraphPad, La Jolla, CA, USA). P , 0.05 was considered to be statistically significant.
RESULTS
VEGF reduces TNF-a-induced lymphocyte adhesion to microvascular endothelial cells under flow
To investigate the role of the proangiogenic factor VEGF in regulation of endothelial activation in microvascular endothelial cells, we studied its effects on TNF-a-induced lymphocyte adhesion to primary HDMEC. We used a microfluidic chamber system, which was designed originally to study endothelial migration toward a growth factor gradient (14, 18) . This microfluidic chamber was modified to allow analysis of leukocyte adhesion to endothelial cells under flow conditions (Fig. 1A, B) . In this setup, Jurkat cells were flowing over the endothelial monolayer at a flow rate of 4 ml/min. Five random positions were monitored every 30 s until the time when leukocyte adhesion on the endothelium was saturated. We observed a striking increase of Jurkat cell adhesion on TNF-a-treated HDMEC compared with untreated cells (Fig. 1C and Supplemental Video). In the presence of VEGF, the number of Jurkat cells adhering to the endothelial monolayer upon TNF-a treatment was reduced significantly (Fig. 1C, D) . This is consistent with previous reports examining the effect of proangiogenic factors on static adhesion of leukocytes to HUVECs (19) and demonstrates that VEGF limits TNF-ainduced endothelial activation and reduces leukocyte adhesion to microvascular endothelial cells under flow conditions.
VEGF reduces TNF-a-induced expression of inflammation-associated genes
To identify genes that mediate the observed VEGFinduced repression of TNF-a-induced leukocyte adhesion, we analyzed global effects on gene expression in HDMEC treated with TNF-a alone and TNF-a combined with VEGF using the Affymetrix microarray. To investigate if the small molecule kinase inhibitor sunitinib, which inhibits VEGFR activation, would restore TNF-a signaling in HDMEC or invoke additional changes in gene expression as a result of potential effects on other signaling pathways, we also included HDMEC treated with TNF-a, combined with VEGF and sunitinib. Through principle component analysis of total gene expression, we found that VEGF altered the TNF-a-induced gene expression pattern and that cotreatment with sunitinib efficiently restored the TNF-a-induced expression profile (Fig. 2A) . In total, 807 genes were significantly up-regulated, and 554 genes were downregulated by TNF-a stimulation in HDMEC. Among these, we identified 86 genes whose up-regulation (28 genes) or down-regulation (58 genes) was repressed significantly by cotreatment with VEGF (Fig. 2B, C) . The majority of these genes included proinflammatory genes, including the chemokines CXCL10 and CXCL11, which are known to serve as chemoattractants for T cells through binding to their common receptor CXCR3 (20) (21) (22) . VEGF-induced repression of gene expression was restored by sunitinib cotreatment (Fig. 2B, C) .
It is notable that TNF-a-induced expression of ICAM-1, VCAM-1, and E-selectin was not detected as significantly repressed by VEGF cotreatment in our microarray analysis of HDMEC. However, these genes have been shown previously to be reduced by VEGF cotreatment in TNFa-treated HUVEC and have been implicated in tumor endothelial cell anergy (4, 13) . Therefore, we analyzed
was maintained until 48 h after stimulation, whereas E-selectin expression reached its maximum 6 h after stimulation (data not shown). VEGF treatment did not affect the basal level of ICAM-1, VCAM-1, or E-selectin expression, and in line with the microarray results, VEGF did not affect TNFa-induced expression of ICAM-1 in HUVEC or HDMEC (Supplemental Fig. 1A, D, H, K) . In contrast, VEGF reduced TNF-a-induced VCAM-1 expression in HDMEC and HUVEC by ;50% after 48 h of stimulation (Supplemental Fig. 1B, E, I, L) . A minor reduction of E-selectin expression was observed in HDMEC and HUVEC cotreated with VEGF and TNF-a compared with cells treated with TNF-a alone (Supplemental Fig. 1C, J) . Inhibition of VEGF signaling by sunitinib cotreatment restored VCAM-1 protein expression (Supplemental Fig. 1F) . A similar reduction in VCAM-1 mRNA expression was noted when TNF-a was combined with VEGF treatment, suggesting that VEGF treatment interferes with pathways leading to transcription of VCAM-1 (Supplemental Fig. 1G ).
Functional annotation of the 86 TNF-a-regulated genes that were reversed by VEGF cotreatment revealed an enrichment of several inflammatory pathways, such as the chemokine signaling pathway, TLR signaling pathway, and B cell receptor signaling pathway ( Table 1) . Thus, VEGF significantly interferes with TNF-a-induced inflammatory signaling through regulation of a wide array of genes involved in inflammation and immune response. To confirm changes further in TNF-a-induced gene expression, Genes were filtered by significance (P , 0.05; control vs. TNF-a; TNF-a vs. TNF-a + VEGF). Colors code for differences in fluorescence intensity. To create the heat map, the expression values of each gene were centered to the median expression value of the samples (black), values that are lower than the median will appear green, and values higher will appear red in the heat map. TNF-a, 1 ng/ml; VEGF, 50 ng/ml; sunitinib, 1 mM.
induced by VEGF cotreatment, mRNA levels of CXCL10, CXCL11, 4-1BB, CSF2, and C1QTNF1 were determined by qRT-PCR analysis. VEGF did not affect expression of any of the analyzed genes when administrated alone but significantly reduced TNF-a-induced gene expression by 60-95% (Fig. 3A-E and Supplemental Fig. 2A-E) . Sunitinib cotreatment restored gene expression to TNFa-induced levels. Consistent with the observed effects on CXCL10 mRNA expression, secretion of CXCL10 protein into the culture medium by HDMEC upon TNF-a treatment was decreased in the presence of VEGF and restored by sunitinib cotreatment (Fig. 3F) . Furthermore, we analyzed the kinetics of CXCL10 and CXCL11 expression upon TNF-a/VEGF treatment and found that CXCL10 and CXCL11 mRNA levels were elevated at 6 h and continued to increase up to 24 h after TNF-a stimulation. VEGF inhibited CXCL10 and CXCL11 mRNA expression throughout 24 h (Fig. 3G, H) . This inhibitory effect depended on the VEGF dose (IC 50 , 3 ng/ml; TNF-a concentration, 1 ng/ml), and the highest inhibition of gene expression (90% inhibition) was achieved at 10 ng/ml VEGF (Fig. 3I) . Taken together, these data show that VEGF inhibits TNF-a-induced regulation of adhesion molecules and several proinflammatory genes and that cotreatment with sunitinib rescues gene expression.
VEGF interferes with TNF-a-induced endothelial activation through negative cross-talk with the NF-kB pathway TNF-a treatment induces gene expression mainly through activation of the NF-kB pathway. Consistent with this, genes regulated by the transcription factor RelA and NF-kB1 were enriched significantly in the TNF-a-induced gene set inhibited by VEGF (data not shown). Therefore, we hypothesized that VEGF inhibits TNF-a-induced endothelial activation by interfering with components of the NF-kB pathway. VEGF did not affect IkB levels when administered alone, but cotreatment with VEGF inhibited TNF-ainduced IkB degradation (Fig. 4A, B and Supplemental  Fig. 2F ). Sunitinib reversed the VEGF-induced inhibition and restored TNF-a-induced IkB degradation. It is well established that IkB degradation is initiated after being phosphorylated by the IKK complex and that the p-IKK complex is necessary for its kinase activity (23) (24) (25) . Therefore, we analyzed p-IKK after VEGF treatment. We found that serine p-IKKa/b was inhibited by cotreatment with VEGF, and sunitinib reversed the inhibition (Fig. 4C, D) .
TNF-a-induced CXCL10 production depends on expression of IRF-1 (26) (27) (28) . IRF-1 is a transcription factor for the chemokines CXCL10 and CXCL11 and binds to IFNsensitive response element (ISRE) sites adjacent to NF-kBbinding sites in the promoters of these genes (29) (30) (31) . To determine if VEGF-mediated inhibition of CXCL10 expression is associated with IRF-1 regulation, we examined IRF-1 expression after stimulation with TNF-a or TNF-a in combination with VEGF. We found that TNF-a induces IRF-1 expression after 2 h of treatment and that cotreatment with VEGF inhibits TNF-a-induced IRF-1 expression (Fig. 4E, F) . VEGF treatment alone did not affect IRF-1 expression (Supplemental Fig. 2G ).
Stat1 has been implicated in induction of CXCL10 and CXCL11 expression in response to IFNs (32) . Stat3, on the other hand, has been shown to counteract the effects of Stat1 and reduce expression of chemokines (33) . To investigate whether Stat1 and/or Stat3 may be involved in the observed reduction of CXCL10 and CXCL11, we analyzed p-Stat1/3 levels in HDMEC and found that p-Stat1 and p-Stat3 was increased upon TNF-a stimulation. Cotreatment with VEGF increased p-Stat3, while significantly decreasing p-Stat1 at 18 h. (Fig. 4E, G, H) .
It has been shown that fibroblast growth factor (FGF) inhibits TNF-a-induced NF-kB signaling through increased activation of p38-MAPK (34) . Similarly, we found that TNF and VEGF induce p-p38 in endothelial cells and that the combination treatment increased p-p38 extensively (Fig. 4I, J) . Importantly, blocking p38 activity by use of the p38 inhibitor SB203580 completely abolished the VEGF-induced reduction in IkB degradation (Fig. 4K, L) .
Sunitinib reversion of the VEGF-induced effects is associated with abolished p-VEGFR2 (Supplemental Fig.  2H ). However, sunitinib targets several other tyrosine kinases, including VEGFR1, platelet-derived growth factor receptor, and c-Kit. To determine if the VEGF-induced inhibition of TNF-a-induced chemokine expression is mediated through VEGFR2, we knocked down the expression of VEGFR2 using small interfering RNA (siRNA) and tested whether the VEGF-mediated decrease in CXCL10 and CXCL11 expression was abolished. Transfection of HDMEC with siRNA to VEGFR2 resulted in efficient silencing of VEGFR2, at the mRNA and protein level for up to 2-3 days (Supplemental Fig. 2I, J) . When VEGFR2 expression was knocked down, VEGF treatment did not result in a suppression of TNF-induced expression of CXCL10 and CXCL11 anymore, demonstrating that the observed effects of VEGF cotreatment occur downstream of VEGFR2 (Supplemental Fig. 2K , L).
Sunitinib treatment increases leukocyte infiltration and increases the expression of VEGF-suppressed inflammatory genes in B16 tumors
VEGF is generally overexpressed in human and mouse tumors, including B16 melanoma. To test the hypothesis that constitutive VEGF stimulation of tumor endothelial cells represses chemokine expression and that inhibition of VEGF signaling reverses this effect, we treated B16 tumorbearing mice with sunitinib for 1 or 4 days. All of the B16 tumors expressed a high level of VEGF and low, yet detectable, level of TNF-a (Supplemental Fig. 3A, B) . In line with our observation that VEGF inhibits TNF-ainduced leukocyte adhesion to endothelial cells (Fig. 1C, D) , we observed a more than 2-fold increase in CD45 + cells in B16 tumors treated with sunitinib for 4 days compared with vehicle-treated tumors and tumors treated with sunitinib for 1 day (Fig. 5A) . As VEGF inhibited TNF-a -induced upregulation of chemokines involved in T-lymphocyte recruitment in HDMEC, we analyzed the number of infiltrating
CD3
+ T cells in B16 tumors. Most CD3 + T cells were observed around the edge of the B16 tumors, whereas considerably fewer cells were present inside of the tumor (data not shown). By quantifying the number of infiltrating T cells inside of the tumor mass, we found an 18-fold increase in the number of CD3 + T cells upon treatment with sunitinib for 4 days compared with vehicle treatment (Fig. 5B) . It is notable that CD3 + cells were infiltrating as clusters surrounding vessels in B16 tumors treated with sunitinib for 4 days, whereas in vehicle-treated or 1 day sunitinib-treated B16 tumors, only sporadic single cells were detected (Fig. 5C) .
To determine if increased leukocyte recruitment in sunitinib-treated tumors was associated with increased vascular expression of proinflammatory genes, we used laser-capture microdissection to isolate vessels from B16 tumors and analyzed gene expression by qRT-PCR. We found that 1 or 4 days of treatment with sunitinib significantly increased the mRNA levels of CXCL10 (2-to 3-fold) and CXCL11 (7-to 8-fold) in B16 tumor vessels (Fig.  6A, B) . As a result of difficulties in obtaining sufficient amounts of mRNA from laser-capture microdissection, genes that were expressed at low levels were not detectable in these samples. Therefore, we analyzed gene expression in the whole tumor tissue and normalized to VE-cadherin expression levels to adjust for differences in vascular density. Genes that were expressed in B16 tumor cells were excluded from the analysis (Supplemental Fig. 3C ). Consistent with a reduced vessel density after antiangiogenic treatment, expression of the endothelial markers CD31 and VE-cadherin was reduced significantly in the tumor tissue after 4 days of sunitinib treatment (Supplemental Fig. 3D, E) . Expression of TNFSF15, CSF2, ICAM-1, VCAM-1, and E-selectin, previously found to be induced by TNF-a and inhibited by costimulation with VEGF-A in Figure 3 . VEGF reduced the TNF-a-induced expression of the inflammatory genes CXCL10, CXCL11, 4-1BB, CSF2, and C1QTNF. A-E) qRT-PCR analysis of inflammatory gene expression in HDMEC treated with TNF-a, TNF-a + VEGF, or TNF-a + VEGF + sunitinib for 18 h. Values represent mRNA expression levels normalized to HPRT (mean + SD) of 3 separate experiments. F) ELISA-based analysis of secretion of CXCL10 by HDMEC in response to treatment with TNF-a and/or VEGF (mean + SD of 2 separate experiments). G and H) CXCL10 and CXCL11 mRNA expression in response to treatment with TNF-a and/or VEGF. I) Inhibition of TNF-a-induced CXCL10 and CXCL11 expression depended on the VEGF dose (IC 50 , 3 ng/ml). A-F) Statistically significant differences were assessed by ANOVA with Tukey correction for multiple comparisons. In all cases, TNF induced a significant increase in the expression of the gene compared with control treatment; however, for clarity of the figure, only the statistically significant differences among TNF, VEGF, and sunitinib treatment are depicted in the figure (*P , 0.05; **P , 0.01; ****P , 0.0001; TNF-a, 1 ng/ml; VEGF, 50 ng/ml; sunitinib, 1mM). Ctrl, Control; Rel, relative. Values represent mean + SD of three separate experiments (*P , 0.05; **P , 0.01; ***P , 0.001; ****P , 0.0001; TNF-a, 1 ng/ml; VEGF, 50 ng/ml; sunitinib, 1 mM; SB203580, 10 mM).
HDMEC, was analyzed in total tumor tissue, and the expression levels were normalized to VE-cadherin. We found that the levels of TNFSF15 and CSF2 were increased significantly (3-fold) after 4 days of treatment with sunitinib (Supplemental Fig. 3F, G) . However, we did not detect any differences in the expression levels of ICAM-1, VCAM-1, and E-selectin in sunitinib-treated B16 tumors (Supplemental Fig. 3H-J) . Altogether, these observations suggest that treatment with sunitinib restores endothelial activation in tumors by restoring the expression of VEGFsuppressed genes, including CXCL10 and CXCL11.
DISCUSSION
The important proangiogenic function of VEGF signaling in physiology and disease is well described, and the molecular pathways orchestrating formation of blood vessels have been studied intensely during the last decades. Much less is known about the potential function of VEGF in modulating inflammatory responses. Here, we show that VEGF-induced repression of TNF-a-induced endotheliallymphocyte interactions is associated with negative crosstalk with the TNF-a-induced NF-kB pathway, as evidenced by reduced p-IKKa/b and decreased degradation of IkBa in the presence of VEGF. Our data show that VEGF suppresses expression of TNF-a-induced genes, including chemokines CXCL10 and CXCL11. Importantly, inhibition of VEGF signaling by sunitinib treatment restored expression of proinflammatory genes in tumor vessels and increased the number of infiltrating CD3 + T-lymphocytes in B16 tumors. Taken together, this suggests that VEGF limits proinflammatory signaling through repression of the NF-kB pathway and that the targeting of VEGF signaling in pathologic conditions may increase infiltration of lymphocytes into inflamed tissues.
There are conflicting data concerning the roles of VEGF in inflammation. On the one hand, several reports show that short-term VEGF stimulation of endothelial cells leads to activation of the NF-kB pathway, up-regulation of adhesion molecules ICAM-1, VCAM-1, and E-selectin, and consequently, increased leukocyte adhesion to endothelial cells (35) (36) (37) . Consistent with this, VEGF infusion in rat brain leads to up-regulation of ICAM-1 expression and leukocyte recruitment, and conditional depletion of VEGF in Müller cells reduces leukostasis and expression of inflammatory biomarkers in diabetic mice (38, 39) . On the other hand, chronic stimulation by proangiogenic molecules, including VEGF, inhibits proinflammatory signaling, as evidenced by decreased levels of adhesion molecules and reduced leukocyte-endothelial interactions (4, 40) . Similarly, increased levels of soluble VEGFR-1 have been associated with sensitization of endothelial cells to proinflammatory cytokines through repression of VEGFsignaling pathways (41) . Interestingly, VEGF-induced NF-kB signaling was shown to induce endothelial activation, whereas PI3K activation had the opposite effect, suggesting that the net effect of VEGF stimulation may depend on cross-talk with other signaling pathways (36) . Our data demonstrate, for the first time, that VEGF interferes directly with TNF-a-induced signaling through reduction of p-IKKa/b and repression of IkB degradation, resulting in modulation of the expression of a large set of genes demonstrated previously to be involved in endothelial activation and lymphocyte recruitment. The VEGFinduced inhibition of TNF-a-induced NF-kB activation is dependent on signaling downstream of VEGFR2 and is abolished by the p38 kinase inhibitor SB203580. This is consistent with a previous report demonstrating that FGF-mediated repression of TNF-a-induced endothelial activation is dependent on sustained p-p38 (34) . The mechanism by which enhanced p38 activation inhibits the NF-kB signaling pathway is still not clear and is an important area of further investigation.
CXCL10 and CXCL11 are IFN-inducible chemokines, and their promoters harbor ISRE and NF-kB-binding sites. Stat1, p48, and IRF-1 have been shown to regulate CXCL10 and CXCL11 transcription in different cell types, and IRF-1 is of particular importance for CXCL10 induction by IFN-b in endothelial cells (31) . We show that the TNF-a-induced IRF-1 expression is reduced in endothelial cells cotreated with VEGF, consistent with reduced NF-kB activation and the presence of an NF-kBbinding site in the IRF-1 promoter (30). Stat1 is phosphorylated in response to TNF-a and likely contributes to a sustained CXCL10 expression. We observed the highest levels of Stat1 activation at late time-points, consistent with the previously reported induction of IFNb expression in response to TNF-a in endothelial cells (32) . VEGF has previously been shown to induce Stat3 activation in microvascular endothelial cells (42) . Consistent with this, VEGF cotreatment increased p-Stat3 and decreased TNF-a-induced p-Stat1 at late time-points. It is interesting that p-Stat3 can inhibit chemokine production by sequestering p-Stat1, inhibiting the binding to the ISRE site in the chemokine promoters (33) . Our results indicate that VEGF inhibits TNF-ainduced expression of chemokines through reduced activation of NF-kB, decreased expression of IRF-1, inhibition of Stat1 activation, and increased Stat3 activation, efficiently blocking transcriptional activation of ISRE and NF-kB-driven promoters (Fig. 6C) .
The understanding that new blood vessel formation is critical for tumor growth and the central role of VEGF in angiogenesis has led to the development of several antiangiogenic drugs targeting VEGF signaling, which are currently approved for treatment of many different types of cancer. However, VEGF-targeting therapy may lead to adverse effects in animal models, increasing tumor aggressiveness and metastatic dissemination (43, 44) . A better understanding of the role of VEGF in modulating endothelial function is clearly needed. Increased Figure 6 . Sunitinib treatment reverses the VEGFinduced suppression of inflammatory genes CXCL10 and CXCL11 in B16 tumors. A and B) B16 tumor-bearing mice were treated with vehicle or sunitinib for 1 day or 4 days, and tumor vessels were isolated from cryostat-cut frozen tissue sections using laser-capture microdissection. qRT-PCR analysis revealed that CXCL10 was upregulated in B16 tumor vessels in mice treated with sunitinib for 4 days (A), and CXCL11 was upregulated after 1 day of sunitinib treatment (B). Values depict mRNA expression normalized to HPRT (vehicle, n = 6; sunitinib 1 day, n = 3; sunitinib 4 days, n = 6; *P , 0.05). C) Schematic representation of the mechanism by which VEGF suppresses TNF-a-induced expression of inflammatory genes.
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knowledge of how antiangiogenic therapy affects endothelial function may lead to new therapeutic approaches for the treatment of cancer. Increased leukocyteendothelial interaction in tumors following antiangiogenic therapy with anginex, endostatin, or angiostatin suggests that these agents could be used to improve immunotherapy of cancer (13) . Our data show that sunitinib treatment reverses the effects of VEGF on TNFa-induced endothelial activation in vitro, leading to upregulation of genes involved in T cell recruitment, including CXCL10 and CXCL11 (45) . Tumor endothelial cells have a differential gene expression than normal endothelial cells and may differ in their response to growth factors compared with cultured endothelial cells (46, 47) . In addition, pericytes have been shown to induce autocrine VEGF signaling in tumor endothelial cells, suggested as a mechanism to evade antiangiogenic therapy (48) . Nevertheless, sunitinib treatment of tumorbearing mice led to up-regulation of proinflammatory genes, including CXCL10 and CXCL11 in the tumor vessels, and improved recruitment of T cells to the inner parts of B16 tumors. This is consistent with a recent report demonstrating that anti-VEGF treatment before T cell infusion was associated with increased efficacy of adoptive immunotherapy in the B16 melanoma model (9) . Our results indicate that the targeting of VEGF in the tumor microenvironment may have a dual effect in inhibiting angiogenesis and increasing endothelial activation in tumor vessels, leading to enhanced T cell recruitment. It is notable that our study shows that treatment with sunitinib for 4 days is sufficient for relieving the VEGF-induced block of endothelial activation in tumors. This supports the use of antiangiogenic agents to increase the efficacy of cancer immunotherapy and warrants studies aimed at finding optimal treatment regiments for this purpose.
